Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 15/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 14/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19435476 | 0.87 | S1PR1 (0.46) | SLC22A12AR | |
| SCHEMBL28383835 | 0.84 | SLC22A12 (0.55) | SLC22A12CYP11B2CYP11B1 | |
| SCHEMBL19562905 | 0.79 | SLC22A12 (0.78) | SLC22A12CYP11B2CYP11B1 | |
| SCHEMBL19435508 | 0.79 | SLC22A12 (0.57) | SLC22A12 | |
| SCHEMBL19435471 | 0.75 | IMPDH2 (0.52) | SLC22A12AR | |
| SCHEMBL28384713 | 0.75 | SLC22A12 (0.69) | SLC22A12CYP11B2CYP11B1 | |
| SCHEMBL19435560 | 0.74 | PDGFRB (0.39) | SLC22A12 | |
| SCHEMBL17899875 | 0.74 | SLC22A12 (1.00) | SLC22A12 | |
| SCHEMBL19435481 | 0.73 | SLC22A12 (0.80) | SLC22A12CYP11B2CYP11B1 | |
| SCHEMBL19435492 | 0.73 | SLC22A12 (0.51) | SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3241822-B1 | URAT1 INHIBITOR | NIPPON CHEMIPHAR CO (JP) | 2021-03-24 | — | — | EP | disclosed |
| CN-107108478-B | URAT1 inhibitors | 日本化学药品株式会社 | 2020-04-24 | — | — | CN | disclosed |
| US-10173990-B2 | URAT1 inhibitor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-3241822-A1 | URAT1 INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2017-11-08 | — | — | EP | disclosed |
| US-20170290795-A1 | URAT1 INHIBITOR | J-PHARMA CO., LTD. (JP) | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290795-A1 | URAT1 INHIBITOR | SLC10A1, XDH, URB2 | SLC22A12 512/4885CYP11B2 1365/4885CYP11B1 785/4885 |
| US-10173990-B2 | URAT1 inhibitor | SLC10A1, XDH, URB2 | SLC22A12 500/4885CYP11B2 1337/4885CYP11B1 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.